How Soda Health Uses Technology to Eliminate Health Inequity

In this episode of Healthcare Rethink, host Brian Urban sits down with Sarah Rumfelt from Soda Health to delve into an exciting topic: addressing social determinants of health to revolutionize the healthcare landscape.

Rumfelt shares how Soda Health leverages data analytics to identify health plan members at risk due to factors like food insecurity, housing instability, and transportation issues. By pinpointing these individuals, they can design targeted interventions and support programs tailored to their specific needs.

Urban and Rumfelt cover:

  • Soda Health’s use of data analytics to identify at-risk health plan members based on social determinants of health and implements targeted interventions and support programs to meet their specific needs.
  • Soda Health’s partnerships with local retailers and food banks in their high-value retail network, ensuring convenient access to nutritious foods for members facing limited options.

To engage and inform members, Soda Health utilizes cutting-edge technology and communication tools. Personalized messages are sent, providing valuable information about available resources, preventive care screenings, and upcoming appointments. By leveraging these innovative solutions, Soda Health not only improves overall health outcomes but also helps health plans meet HEDIS measures—a set of standardized quality performance metrics used to assess care delivery.

Rumfelt also highlights how Soda Health’s platform assists health plans in achieving specific goals, such as increasing childhood immunization rates. By identifying children at risk of missing vaccinations due to barriers like transportation issues, they offer transportation assistance and coordinate mobile clinics in underserved areas. Closing these gaps in HEDIS measures leads to improved care quality and the potential for higher quality bonus payments from regulatory agencies like CMS.

Looking ahead, Soda Health aims to expand its high-value retail network and forge partnerships with community organizations. Through their commitment to addressing social determinants of health using data analytics and innovative interventions, they aspire to eliminate health inequities and improve access to care for vulnerable populations.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More